ArticleDer Urologe. Ausg. A2009
[The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics].
Article in Der Urologe. Ausg. A, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03943602 (Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)
Who cites it
14 citing papers in PubMed.
- [Current diagnostics and treatment of penile cancer].Urologie (Heidelberg, Germany) · 2026Review
- Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens.Cancers · 2025Review
- Systemic treatment of penile squamous cell carcinoma-hurdles and hopes of preclinical models and clinical regimens: a narrative review.Translational andrology and urology · 2021Review
- [Quality of care criteria in the treatment of penile cancer].Der Urologe. Ausg. A · 2021Review
- [Penile cancer : Diagnosis and treatment].Der Urologe. Ausg. A · 2020Article
- Evaluation of Paclitaxel, Ifosfamide, and Cisplatin (TIP) Regimen on Penile Cancer in Adam Malik Medan: A Single Center 2 Years of Experience.Open access Macedonian journal of medical sciences · 2019Article
- Rare cancers: Challenges & issues.The Indian journal of medical research · 2017Review
- Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?Urology annals · 2014Article
- [Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer].Der Urologe. Ausg. A · 2013Article
- [National second-opinion network for testicular cancer patients. Results of a user survey].Der Urologe. Ausg. A · 2013Article
- Penile cancer: current therapy and future directions.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Review
- [Penile carcinoma: diagnosis and therapy].Der Urologe. Ausg. A · 2013Article
- Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer.Urology annals · 2012Article
- Chemotherapy in penile cancer.Therapeutic advances in urology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe prognosis for advanced penile carcinomas is extremely poor. Due to the low response rates and relevant side effects of current chemotherapy regimens, several attempts have been made to improve chemotherapy in recent years. In a retrospective survey the current state of the art of chemotherapy for penile carcinoma in Germany was analysed.
methodsThe study took the form of a retrospective survey among all urological departments in Germany. The questionnaire contained seven questions concerning indications and modalities for chemotherapy of penile carcinoma in addition to general questions.
resultsOut of 280 departments 129 (46%) returned an answered questionnaire. Chemotherapy was reported to be carried out by 91 of the answering departments and overall 18 different chemotherapy regimens were used. The regimens cisplatin/methotrexate/bleomycin, vinblastin/methotrexate/bleomycin and cisplatin/5FU were the most frequently reported. Chemotherapy was carried out on average 2.3 times per year per department. The majority of the departments reported response rates under 30%. Finally 101 of the answering departments confirmed the necessity of new chemotherapy regimens.
conclusionsThe current state of the art for chemotherapy of penile carcinoma showed a very large variation in Germany. The response rates were disappointing. A nationwide study with new chemotherapy approaches is urgently needed (information under www.uni-rostock.de/peniskarzinom).
Indexed as
Identifiers
19774356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.